Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. We studied the clinical and hemodynamics effects of transitioning 12 pulmonary hypertension patients from Phosphodiesterase type 5 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davey, Ryan, Benza, Raymond L., Murali, Srinivas, Raina, Amresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467945/
https://www.ncbi.nlm.nih.gov/pubmed/28597779
http://dx.doi.org/10.1177/2045893217708566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467945/
https://www.ncbi.nlm.nih.gov/pubmed/28597779
http://dx.doi.org/10.1177/2045893217708566

Ejemplares similares